April 17-22, 2026, American Association for Cancer Research

1) Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers

2) Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for treating SMARCA4 mutant cancers

3) Selective degradation of SMARCA4 as a therapeutic strategy in SMARCA4 driven cancers